Biotech Values

[ghmm]

Is it odd that one of comparators is looking at a side effect of an approved drug?

I can't recall seeing other (HCV) companies go back to Phase 1 to check out a safety signal.

I am guessing part of it may be that companies see the bar being raised for 2nd to market compounds. But I wonder if J&J really feels strongly about this compound or if they just don't have anything else far enough along (aside from their Vertex x-US deal).